Submitted by:
Name: Raul Diez-Fernandez
Company/Organization: Hospital Universitario de Getafe
Address: Ctra de Toledo km 12.500 28905 Getafe, Madrid (Spain)
Phone: +34616483933
Email: raul.diez@salud.madrid.org
Date of request: 20th of October 2015
NCCN Guidelines Panel: Myeloid Growth Factors version 1.2015

On behalf of Hospital Universitario de Getafe, we respectfully request the NCCN (Myeloid Growth Factors version 1.2015) to review some discrepancies found on such guideline with regards to Examples of Disease Settings and Chemotherapy Regimens according to the risk of febrile neutropenia.

Specific Changes:

After a systematic review, which is going to be published on the next issue of the “European Journal of Clinical Pharmacy”, of all scientific literature published in the last 20 years of phase III clinical trials evaluating the use of taxanes in the treatment of breast cancer that we have just conducted we have come to find some discrepancies with the NCCN “Myeloid Growth Factors 1.2015 version” guidelines.

On the MGF-A section, “Examples of Disease Settings and Chemotherapy Regimens with a High Risk for Febrile Neutropenia (20%)”, docetaxel combined with trastuzumab has been included based on a phase II trial that included 186 patients1.

Based on our pooled analyses that included 565 patients from 5 treatment arms from 4 phase III clinical trials2-5 we concluded the real incidence of febrile neutropenia would be 16.3%, below the 20% threshold necessary for a category 1 recommendation. According to our results it should be classified as an Intermediate Risk.

On our analysis, four phase III clinical trials7-10, including 4,567 patients, were evaluated. The incidence of febrile neutropenia was 1.1% and it was only 0.6%, when the results of one arm of treatment evaluating a 225 mg/m2 schedule were excluded.

Paclitaxel every 21 days (metastatic or relapsed) is also included as an intermediate risk regimen based on a phase II trial28 with 49 patients who started on a 250 mg/m2 dose, and only those patients with previous treatment started on the more frequently used 175 mg/m2 schedule. Febrile neutropenia occurred in only four cycles (3.6%) among three patients.
Furthermore, our analyses including 1,379 patients from 7 phase III clinical trials\textsuperscript{12,13,29-33} showed that the highest incidence reported was 7\%.

The following articles are submitted in support of this proposed change. We would like to acknowledge the contributions of NCCN panel members who might also be co-authors or co-contributors of some of these publications.


Yours sincerely,

Raúl Diez Fernández

Santos Enrech Frances

Teresa Molina Garcia